Veracyte Inc (FRA:12V)
€ 32 0.6 (1.91%) Market Cap: 2.54 Bil Enterprise Value: 2.34 Bil PE Ratio: 0 PB Ratio: 2.37 GF Score: 83/100

Veracyte Inc at Morgan Stanley Global Healthcare Conference Transcript

Sep 13, 2022 / 06:55PM GMT
Release Date Price: €19.51 (+2.58%)
Tejas Rajeev Savant
Morgan Stanley, Research Division - Equity Analyst

Hello, everyone. Good afternoon. My name is Tejas Savant. I cover life science tools and diagnostics here at Morgan Stanley. It's my pleasure to host Veracyte this afternoon, and representing the company, we have Marc and Rebecca, CEO and CFO. It's great to have you both.

Before we dig into questions, quickly the research disclosures. Please see the Morgan Stanley research disclosure website at morganstanley.com/researchdisclosures. If you have any questions, do reach out to your sales rep.

Questions & Answers

Tejas Rajeev Savant
Morgan Stanley, Research Division - Equity Analyst

Right. So Marc, maybe just to start, you've been about a year in the hot seat now. What do you view as Veracyte's key accomplishments over the last 12 months? And what are you most excited about heading into '23?

Marc A. Stapley
Veracyte, Inc. - CEO & Director

Thanks, Tejas. Thanks for having us here today as well. Appreciate it. Before I dig

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot